The 2 hormones responsible for the amplification of insulin secretion after oral as opposed
to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) …

Abstract Glucagon-like peptide-1 receptor (GLP-1R) is a well-studied incretin hormone
receptor and target of several therapeutic drugs for type 2 diabetes (T2D), obesity and, more …

Receptors for the peptide hormones glucagon-like peptide-1 (GLP-1R), glucose-dependent
insulinotropic polypeptide (GIPR), and glucagon (GCGR) are important regulators of insulin …

Appetite control has been an important target for the treatment of obesity and associated
disorders. New studies have demonstrated promising adoption of dietary approaches …

Introduction One billion people live with obesity. The most promising medications for its
treatment are incretin-based therapies, based on enteroendocrine peptides released in …

The incretin hormones: glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) are important regulators of many aspects of metabolism including …

Glucose-dependent insulinotropic polypeptide (GIP) is a gut-derived incretin that, in
common with glucagon-like peptide-1 (GLP-1), has both insulin releasing and extra …

Aging is a highly complex molecular process, affecting nearly all tissue systems in humans
and is the highest risk factor in developing neurodegenerative disorders such as Alzheimer's …

Introduction There are no drugs approved by regulatory agencies for the treatment of
nonalcoholic fatty liver disease (NAFLD); incretin combination therapies are being …

G protein-coupled receptors (GPCRs) are major disease-relevant drug targets; robust
monitoring of their activities upon drug treatment is key to drug discovery. The split TEV cell …